Physician profile
James C Brock
NPI 1790711711
$3,544.19
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $333 · 2021: $835 · 2022: $499 · 2023: $771 · 2024: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.73 | 2019-2024 | Lo Loestrin Fe |
| Intuitive Surgical, INC. | $486.36 | 2019 | |
| Hologic Sales and Service, LLC | $303.75 | 2019-2024 | Acessa Provu System, Aptima, Myosure Tissue Removal Device |
| Aspira Women'S Health INC | $242.56 | 2021 | |
| Mayne Pharma Commercial LLC | $180.96 | 2021-2023 | |
| Coopersurgical, INC. | $155.11 | 2019-2023 | Paragard T 380a |
| Myriad Women'S Health, INC. | $126.18 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $122.77 | 2019-2023 | |
| Astellas Pharma US INC | $120.59 | 2019-2024 | Veozah, Myrbetriq |
| Scynexis, INC. | $112.40 | 2021-2022 | |
| Exeltis, USA INC. | $83.85 | 2020-2023 | Slynd |
| Mylan Pharmaceuticals INC. | $76.44 | 2019-2022 | |
| Daiichi Sankyo INC. | $72.60 | 2019-2021 | |
| Therapeuticsmd, INC. | $68.06 | 2019-2022 | |
| Pfizer INC. | $67.97 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $65.57 | 2020-2023 | Surgiflo Hemostatic Matrix |
| Evofem Biosciences, INC. | $58.21 | 2021-2022 | |
| Radius Health, INC. | $44.04 | 2019 | |
| Amgen INC. | $41.81 | 2019-2020 | |
| Roche Diagnostics Corporation | $41.27 | 2019-2021 | |
| Agile Therapeutics, INC. | $40.91 | 2021-2023 | Twirla |
| Lundbeck LLC | $37.22 | 2021 | |
| Millicent US INC | $37.08 | 2023 | Intrarosa |
| Shield Therapeutics INC | $35.20 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $32.98 | 2023-2024 | Myfembree |
| Baxter Healthcare | $23.26 | 2019 | |
| Virtus Pharmaceuticals LLC | $19.50 | 2022 | |
| Monaghan Medical Corporation | $18.34 | 2023 | Aerochamber |
| Medicem INC. | $18.02 | 2020 | |
| Meditrina | $15.33 | 2022 | |
| Exact Sciences Corporation | $14.75 | 2023 | Cologuard Collection Kit |
| Zyla Life Sciences, INC. | $14.49 | 2020 | |
| Myovant Sciences INC. | $13.71 | 2022 | |
| Alydia Health | $13.55 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.19 | 2019 | |
| Lupin INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.